Benjamin L Palleiko Kal Vista Pharmaceuticals, Inc. (KALV) insider trading activity

Benjamin L Palleiko is CHIEF EXECUTIVE OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 416,189 shares of KALV, which is worth approximately $5.54 Million. The most recent transaction as insider was on Nov 24, 2025, when has been sold 10,940 shares (Common Stock) at a price of $13.45 per share, resulting in proceeds of $147,143. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 416K

7.58% 3M change

56.11% 12M change

Total Value Held $5.54 Million

Benjamin L Palleiko Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 24 2025	SELL Open market or private sale	$147,143 $13.45 p/Share	10,940 Reduced 2.56%	416,189 Common Stock
Nov 21 2025	BUY Exercise of conversion of derivative security	-	23,250 Added 5.16%	427,129 Common Stock
Nov 18 2025	SELL Open market or private sale	$64,667 $14.48 p/Share	4,466 Reduced 1.09%	403,879 Common Stock
Nov 17 2025	BUY Exercise of conversion of derivative security	-	9,364 Added 2.24%	408,345 Common Stock
Nov 12 2025	SELL Open market or private sale	$38,438 $11.55 p/Share	3,328 Reduced 0.83%	398,981 Common Stock
Nov 11 2025	BUY Exercise of conversion of derivative security	-	7,120 Added 1.74%	402,309 Common Stock
Sep 08 2025	SELL Open market or private sale	$115,536 $15.84 p/Share	7,294 Reduced 1.81%	395,189 Common Stock

Sep 06 2025	BUY Exercise of conversion of derivative security	-	15,625 Added 3.74%	402,483 Common Stock
Aug 22 2025	SELL Open market or private sale	$144,626 $13.22 p/Share	10,940 Reduced 2.75%	386,858 Common Stock
Aug 21 2025	BUY Exercise of conversion of derivative security	-	23,250 Added 5.52%	397,798 Common Stock
Aug 18 2025	SELL Open market or private sale	$58,154 $13.19 p/Share	4,409 Reduced 1.16%	374,548 Common Stock
Aug 17 2025	BUY Exercise of conversion of derivative security	-	9,362 Added 2.41%	378,957 Common Stock
Jul 09 2025	SELL Open market or private sale	$517,440 $15.69 p/Share	32,979 Reduced 8.19%	369,595 Common Stock
Jul 08 2025	BUY Grant, award, or other acquisition	-	87,500 Added 17.85%	402,574 Common Stock
Jun 09 2025	SELL Open market or private sale	$103,950 $14.5 p/Share	7,169 Reduced 2.22%	315,074 Common Stock
Jun 06 2025	BUY Exercise of conversion of derivative security	-	15,625 Added 4.62%	322,243 Common Stock
May 22 2025	SELL Open market or private sale	$118,788 $11.88 p/Share	9,999 Reduced 3.16%	306,618 Common Stock
May 21 2025	BUY Exercise of conversion of derivative security	-	23,250 Added 6.84%	316,617 Common Stock
May 19 2025	SELL Open market or private sale	$45,086 $11.84 p/Share	3,808 Reduced 1.28%	293,367 Common Stock
May 17 2025	BUY Exercise of conversion of derivative security	-	9,364 Added 3.05%	297,175 Common Stock
Mar 07 2025	SELL Open market or private sale	$79,827 $11.97 p/Share	6,669 Reduced 2.26%	287,811 Common Stock
Mar 06 2025	BUY Exercise of conversion of derivative security	-	15,625 Added 5.04%	294,480 Common Stock
Feb 18 2025	SELL Open market or private sale	$50,121 $9.82 p/Share	5,104 Reduced 1.8%	278,855 Common Stock
Feb 17 2025	BUY Exercise of conversion of derivative security	-	9,363 Added 3.19%	283,959 Common Stock
Dec 09 2024	SELL Open market or private sale	$74,363 $9.75 p/Share	7,627 Reduced 2.7%	274,596 Common Stock

BLP

Benjamin L Palleiko

CHIEF EXECUTIVE OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Value

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

Operation

Value

Type

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV

Account